Suven Life Sciences Limited (SUVEN) shares positive topline results from Phase-2b trial of Ropanicant for Major Depressive Disorder.
Suven Life Sciences Limited (NSE: SUVEN) successfully completes Phase-1 study for SUVN-I6107, advancing to Phase-2.
Suven Life Sciences Limited (SUVEN) announces three poster presentations on Samelisant at SLEEP-2026 Annual Meeting in Baltimore, showcasing clinical advance.
Suven Life Sciences Limited (SUVEN) announces positive DSMB safety review and interim analysis from ongoing global Phase 3 study of Masupirdine in Alzheimer'.
Suven Life Sciences Limited reaches 76% enrollment in its Global Phase 3 Masupirdine trial for Alzheimer’s agitation.
